

Abstract Form

Medical Research
Nursing Research



American Heart
Association

1985

Number

32

Please do not fill in!

1985 Nursing Res 29:238

THE AMERICAN HEART ASSOCIATION'S 57th SCIENTIFIC SESSIONS

November 12-15, 1984
Miami Beach Convention Center
Miami Beach, Florida

Please read instructions
before typing abstract.

Deadline Date: Abstracts must be postmarked
no later than Monday, May 14, 1984.

Abstract of paper to be considered for presen-
tation at the 57th Scientific Sessions, Novem-
ber 12-15, 1984, Miami Beach, Florida.

For review and grading, assign this abstract to
the Grading Category List number listed
below:

Choice 1

Choice 2

53

4

Number

Number

Identify two key words or phrases to be used
for indexing in the supplement to *Circulation*,
an AHA journal:

1. Hypertension
2. Microcirculation

The author affirms that the material herein will not have
been previously published as a manuscript or presented
at any national meeting, that any animal studies conform
with the "Guiding Principles in the Care and Use of
Animals" of the American Physiological Society and that
any human experimentation has been conducted accord-

ing to a protocol approved by the institutional committee
on ethics of human investigation or — if no such commit-
tee exists — that it conforms with the principles of the
Declaration of Helsinki of the World Medical Association
(*Clinical Research* 14:193, 1966).

Author's signature

The undersigned certifies that all authors named in this
abstract have agreed to its submission for presentation
at the AHA Scientific Sessions.

Author's signature

MICROVASCULAR EFFECTS OF CHRONIC VERAPAMIL
TREATMENT IN SPONTANEOUSLY HYPERTENSIVE RAT

Harvey N. Mayrovitz, John Roy, Berta
Herscovici, Ronald Sampsell.

Miami Heart Institute, Miami Beach, FL

Verapamil was given via subcutaneously
implanted osmotic minipumps for 2 weeks at a
continuous dose of 0.85mg/100gm/day. Thereafter,
direct observation and measurements in the rat
cremaster microvasculature of the verapamil
treated group (VERAP, n=11, 6-7 wks) were
compared with a sham implanted group
(SHAM, n=11). Arteriolar diameter (D), blood
flow (Q), and micropressure (P) were determined
in 3 branching orders (A1, A2, A3), under control
conditions (CC), maximal dilation (MD), and after
graded doses (2-1000 nM) of topically applied
norepinephrine (NE). The VERAP group had a lower
heart rate (333 vs 370/min, $p < 0.01$), and lower
mean systemic blood pressure (111 vs 124 mmHg,
 $p < 0.01$), but the fraction of this pressure
transmitted to A2 in the VERAP group was
greater (44 vs 37%, $p < 0.01$) as were the VERAP
A1 diameters under CC (71 μ m vs 64 μ m, $p < 0.05$).
These were the only differences between groups
under CC. With MD, Q increases and P decreases
were noted at all branching levels, but no
further differences between groups were found.
There were no differences in the responses of
any parameter to NE challenge. The results
suggest that the main vascular component of the
antihypertensive action of verapamil resides in
vessels upstream from the microvasculature.